Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).

Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K; BEAUTIFUL Investigators.

Am J Cardiol. 2011 Mar 15;107(6):805-11. doi: 10.1016/j.amjcard.2010.10.065. Epub 2011 Jan 19.

PMID:
21247517
2.

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators.

Eur Heart J. 2009 Oct;30(19):2337-45. doi: 10.1093/eurheartj/ehp358. Epub 2009 Aug 31.

3.

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators.

Lancet. 2008 Sep 6;372(9641):817-21. doi: 10.1016/S0140-6736(08)61171-X. Epub 2008 Aug 29.

PMID:
18757091
4.

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators.

Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29.

PMID:
18757088

Supplemental Content

Loading ...
Write to the Help Desk